- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07465172
GDF-15 и его связь с нежелательными явлениями, связанными с лечением рака молочной железы (GRADE)
Многоцентровое проспективное когортное исследование по изучению взаимосвязи между изменениями уровня GDF-15 и нежелательными явлениями, связанными с лечением, во время терапии T-DXd у пациентов с раком молочной железы.
GRADE is trying to find out if there is a link between a hormone called GDF-15 and the side effects that people can experience when taking T-DXd.
GDF-15 can be measured in the blood. GDF-15 levels in the blood will go up when the body is stressed under certain conditions, including breast cancer. There is a link between high GDF-15 levels and the nausea and vomiting experienced with "morning sickness" in pregnancy. It has also been shown that GDF-15 levels will go up with the use of other types of chemotherapy that are known to cause nausea and vomiting.
Side effects such as feeling sick (nausea), vomiting and weight loss are common with T-DXd. Sometimes, these can be so severe that treatment needs to be stopped early. The investigators can't predict who will get bad side effects and who will not.
If the investigators can find out if there is a link between GDF-15 and the side effects of T-DXd, they can use this information in future clinical trials.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Growth differentiation factor 15 (GDF-15), a stress-related hormone also known as macrophage inhibitory cytokine-1 (MIC-1), is a member of the transforming growth factor-beta (TGF-β) superfamily. It is not expressed under basal conditions but can be released in response to pro-inflammatory conditions such as obesity, insulin resistance, renal and heart failure, and malignancy.
Pre-clinical studies have established the role of elevated GDF-15 levels in tumour and platinum-based chemotherapy induced emesis and cachexia. It has also been proposed as a biomarker for all-cause mortality, as well as for poor prognoses in patients with cancer.
The hypothesis is that there is a positive correlation between increased levels of GDF-15 and the severity of treatment-related adverse events (particularly nausea, vomiting and cachexia) experienced by patients with breast cancer receiving T-DXd.
The aim of the study is to explore the relationship between relative change in levels of GDF-15 from baseline (pre-treatment) to after receiving T-DXd (post-C2 and at end of treatment) and the severity of treatment-related adverse events experienced by patients with breast cancer receiving T-DXd.
If a positive relationship is found with any or all of these objectives, then monoclonal antibodies inhibiting GDF-15 (such as ponsegromab or visugromab) may present a promising therapeutic and supportive option for patients receiving T-DXd.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Tracey Hay
- Номер телефона: +61 (0) 2 4925 5277
- Электронная почта: tracey.hay@bctrials.org.au
Учебное резервное копирование контактов
- Имя: Michelle Li, Dr
- Номер телефона: +61 (0) 3 8559 5935
- Электронная почта: michelle.li@petermac.org
Места учебы
-
-
New South Wales
-
Newcastle, New South Wales, Австралия, 2290
- Lake Macquarie Private Hospital
-
Контакт:
- Nick Zdenkowski, Dr
- Номер телефона: +61 (02) 4942-2600
- Электронная почта: nick.zdenkowski@newcastle.edu.au
-
Главный следователь:
- Nick Zdenkowski, Dr
-
-
Victoria
-
Melbourne, Victoria, Австралия, 3000
- Peter MacCallum Cancer Centre
-
Контакт:
- Sherene Loi, Prof
- Номер телефона: +61 (03) 8559-5935
- Электронная почта: sherene.loi@petermac.org
-
Главный следователь:
- Sherene Loi, Prof
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Dana-Farber Cancer Institute
-
Контакт:
- Michelle Li, Dr
- Номер телефона: +61 (0) 3 8559 5935
- Электронная почта: michelle.li@petermac.org
-
Главный следователь:
- Michelle Li, Dr
-
-
-
-
-
Okayama, Япония, 700-8558
- Okayama University Hospital
-
Контакт:
- Tadahiko Shien, Prof
- Номер телефона: +81 (08) 62357265
- Электронная почта: tshien@md.okayam-u.ac.jp
-
Главный следователь:
- Tadahiko Shien, Prof
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Participants aged ≥18 years.
- Histologically confirmed diagnosis of metastatic/advanced unresectable HER2-positive or HER2-low breast cancer.
- Planned to start treatment with T-DXd.
- Life expectancy of at least 4 months.
Exclusion Criteria:
- Current active reversible causes of decreased food intake, as determined by the Investigator.
- Receiving tube feedings or any kind of parenteral nutrition at the time of enrolment into the study.
- Ongoing cachexia attributable to other reasons unrelated to cancer or cancer treatment as determined by the Investigator that may confound interpretation of weight loss due to T-DXd.
- Current adherence to a calorie-restricted diet with the intention of weight loss.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Поддерживающая терапия
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Другой: Blood Collection for GDF-15
Blood collection for GDF-15 during T-DXd treatment. |
Blood samples of 20-30mL (approximately 1-2 tablespoons in total) will be taken 4 times:
At each blood collection, participants will be asked about:
Personal and health information will also be collected from participants:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Nausea prior to Cycle 3 of T-DXd, graded according to Common Terminology Criteria for Adverse Advents (CTCAE) v5.0.
Временное ограничение: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade nausea (CTCAE Grade 2-4) experienced at this timepoint by patients with metastatic/advanced unresectable HER2-positive or HER2-low breast cancer. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Vomiting prior to Cycle 3 of T-DXd, graded as per CTCAE v5.0.
Временное ограничение: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade vomiting (CTCAE Grade 2-4) experienced by patients at this timepoint. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Weight loss (cachexia) prior to Cycle 3 of T-DXd, graded as per CTCAE v5.0.
Временное ограничение: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To investigate if the percentage change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with moderate/high grade cachexia (CTCAE Grade 2-4) experienced by patients at this timepoint. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Percentage change in GDF-15 and its correlation with treatment-related adverse events (TRAEs)
Временное ограничение: From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
To explore the correlation of the percentage change in levels of GDF-15 with the treatment-related adverse events (CTCAE Grade 2-4). Treatment-related adverse events (TRAEs) are adverse events classified as possibly, probably or definitely related to T-DXd treatment. TRAEs will be graded as per CTCAE v5.0. |
From baseline to after receiving 2 cycles of T-DXd treatment (each cycle is 28 days).
|
|
Progression-free survival (PFS)
Временное ограничение: Time from treatment start with T-DXd to the first occurrence of disease progression or death due to any cause, whichever came first, assessed up to 6 months.
|
To explore the relationship between baseline levels of GDF-15 and progression-free survival (PFS) on T-DXd |
Time from treatment start with T-DXd to the first occurrence of disease progression or death due to any cause, whichever came first, assessed up to 6 months.
|
|
Time to treatment failure (TTF)
Временное ограничение: Time from treatment start with T-DXd to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death, whichever came first, assessed up to 6 months.
|
To explore the relationship between baseline levels of GDF-15 and time to treatment failure (TTF) on T-DXd. |
Time from treatment start with T-DXd to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death, whichever came first, assessed up to 6 months.
|
|
HER2 copy number
Временное ограничение: Prior to treatment commencement.
|
To explore the relationship between HER2 copy number and change in levels of GDF-15. HER2 copy number determined by in-situ hybridization (ISH) on most recent available histopathology specimen or tumour/plasma genomic data (DNA/RNA), preferably in the metastatic setting |
Prior to treatment commencement.
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Exploratory: Association of baseline levels of GDF-15 with Treatment Related Adverse Events (TRAEs).
Временное ограничение: TRAEs occurring after Cycle 2, after Cycle 3 and within 30 days of end of treatment with T-DXd (each cycle is 28 days).
|
To explore if baseline levels of GDF-15 are associated with the incidence and severity of TRAEs experienced by patients on T-DXd, graded as per CTCAE v5.0. |
TRAEs occurring after Cycle 2, after Cycle 3 and within 30 days of end of treatment with T-DXd (each cycle is 28 days).
|
|
Exploratory: Longitudinal change in weight after 2 cycles of T-DXd
Временное ограничение: After receiving 2 cycles of T-DXd (each cycle is 28 days).
|
To explore if the longitudinal change in levels of GDF-15 from baseline to after receiving 2 cycles of T-DXd is associated with trends in weight change. Weight change is measured as a percentage of baseline weight. End-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity. |
After receiving 2 cycles of T-DXd (each cycle is 28 days).
|
|
Exploratory: Longitudinal change in weight at end-of-treatment
Временное ограничение: At end-of-treatment with T-DXd; end-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity, whichever came first, assessed up to 6 months.
|
To explore if the longitudinal change in levels of GDF-15 from baseline at end-of-treatment with T-DXd is associated with trends in weight change. Weight change is measured as a percentage of baseline weight. |
At end-of-treatment with T-DXd; end-of-treatment is defined as cessation of treatment due to disease progression or treatment toxicity, whichever came first, assessed up to 6 months.
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Heath Badger, Breast Cancer Trials, Australia and New Zealand
- Учебный стул: Sherene Loi, Prof, Peter MacCallum Cancer Centre, Australia
- Учебный стул: Michelle Li, Dr, Peter MacCallum Cancer Centre, Australia
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Масса тела
- Признаки и симптомы, пищеварительный тракт
- Изменения массы тела
- Кожные заболевания
- Заболевания груди
- Патологические состояния, признаки и симптомы
- Заболевания кожи и соединительной ткани
- Признаки и симптомы
- Потеря веса
- Новообразования молочной железы
- Тошнота
- Рвота
- Пептиды
- Аминокислоты, пептиды и белки
- Белки
- Биологические факторы
- Межклеточные сигнальные пептиды и белки
- Цитокины
- Факторы дифференцировки роста
- Белки суперсемейства TGF-бета
- Фактор дифференцировки роста 15
Другие идентификационные номера исследования
- BCT 2502
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Anonymised Individual Patient Data (IPD) collected during the trial.
Сроки обмена IPD
Data will be made available for request after publication of the main/final study results; no end date.
Критерии совместного доступа к IPD
Researchers who submit a research proposal and BCT Data Request Application, which is assessed by BCT to have appropriate scientific value. Applications will be subject to approval by Breast Cancer Trials concept@bctrials.org.au (refer to BCT Data Sharing Guidelines).
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- АНАЛИТИЧЕСКИЙ_КОД
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .